ChartRow logo
NVS
$164.98+3.59%
as of close, Nov 4, 2026
☾ AH $164.98 +3.59%
PeersAMGNNVOMRKABBVGILDPFE
Share this page

NVS — Novartis AG price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
What would $1,000 invested in NVS be worth today? →
NVS returns: By year · By month · By week · Trailing

Key stats#

Price data

Price
$164.98
YTD price return
+19.66%
YTD total return
+23.31%
Market cap
314.8B
Enterprise value
304.2B
Shares outstanding
1.9B
52W low
$123.24
52W high
$170.46
From 52W high
-3.21%
From 52W low
+33.87%
52W range
88%$123–$170
Beta
0.46

Volume

Rel volume
0.87×
30D volume
2M
30D $ vol
299.5M

Fundamentals

EPS (ttm)
$7.15
FCF (ttm)
17.6B
FCF/share
$9.22
Book value/share
$24.18
ROE
30.28%
ROA
12.59%
Current ratio
1.12

Growth (CAGR, ttm) · 10Y

Net income
+17.00%+26.16%+11.59%n/a
FCF
+8.27%+9.72%+7.29%n/a
Shares
-3.39%-3.44%-3.30%n/a

Per-share growth (CAGR, ttm) · 10Y

EPS
+21.82%+31.14%+15.23%n/a
FCF/share
+12.07%+13.63%+10.96%n/a
Book value/share
+8.41%-4.77%-0.73%n/a
Dividend/share
+6.15%+4.98%+5.76%n/a
Price
+32.00%+21.13%+14.54%+10.17%
Total return
+36.02%+25.35%+18.88%+14.22%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
23.1×
P/OI (ttm)
17.8×
Fwd P/E
16.5×
P/B (mrq)
6.8×
P/FCF (ttm)
17.9×
EV/EBITDA (fy)
17.2×
FCF yield (ttm)
5.59%
Dividend yield (fwd)Div yield
2.89%
Dividend yield (ttm)
2.89%
Dividend/share (fwd)
$4.77
Buyback yield (realized, 1y)
3.39%
Shareholder yield (realized, 1y)
7.46%
Buyback yield (cash, ttm)
2.90%
Shareholder yield (cash, ttm)
5.38%

Vs own 10Y history

P/E
65th
P/OI
21st
P/B
100th
P/FCF
93rd

Bar = where today’s multiple sits in NVS’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-04#

1D
+3.59%
5D
+5.70%
1M
+17.01%
3M
+7.64%
YTD
+19.66%
1Y
+31.97%
5Y
+97.13%
1D
+3.59%
5D
+5.70%
1M
+17.01%
3M
+7.64%
YTD
+23.31%
1Y
+35.99%
5Y
+137.43%

Fundamentals#

Net income

5Y CAGR +11.6%5Y CAGR +11.6%
$14B FY25
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating income

5Y CAGR +11.7%5Y CAGR +11.7%
$17.6B FY25
FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

EPS (diluted)

5Y CAGR +15.2%5Y CAGR +15.2%
$7.15 FY25
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Free cash flow

5Y CAGR +7.3%5Y CAGR +7.3%
$17.6B FY25
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

FY25: operating cash flow $19.1B, capex −$1.5B

No quarters filed for this figure.

Shares (diluted)

5Y −14.9%5Y −14.9%
2B FY25
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Dividend per share

5Y CAGR +5.8%5Y CAGR +5.8%
$4.10 FY25
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Full NVS financials →

About Novartis#

Novartis AG Sponsored ADR represents Novartis AG, a global healthcare company focused on developing, manufacturing, and commercializing prescription medicines and related healthcare products. Novartis serves major therapeutic areas including oncology, immunology, cardiovascular, neuroscience, and ophthalmology, with a portfolio built around innovative treatments for serious and chronic diseases. The company operates across research, development, production, and global distribution, supporting hospitals, physicians, and patients in markets worldwide. Novartis also includes medicines and platforms designed to improve access, formulation, and delivery of therapies, making it a significant participant in the pharmaceutical industry and the broader healthcare market. As a sponsored ADR, it provides U.S. investors with access to Novartis shares through an American depositary receipt structure.

Basel, Switzerland·75,267 employees·Drug Manufacturers - General·novartis.com·As of Oct 28, 2026

Recent filings#

No earnings release, press release or insider trade outside a 10b5-1 plan in the last 120 days.

All filings and insider trades →

ETFs holding NVS#

11 of the 193 ETFs ChartRow carries live hold NVS. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
EWLiShares MSCI Switzerland ETF12.3%
VIGIVanguard International Dividend Appreciation ETF3.5%
VGKVanguard FTSE Europe ETF1.8%
VYMIVanguard International High Dividend Yield ETF1.5%
EFAiShares MSCI EAFE ETF1.3%
VEAVanguard FTSE Developed Markets ETF0.9%
VEUVanguard FTSE All-World ex-US ETF0.7%
VXUSVanguard Total International Stock ETF0.7%
TickerName1M1D
LLYEli Lilly and Company+24.07%+0.61%
JNJJohnson & Johnson+7.92%+3.81%
ABBVAbbVie Inc.+12.18%+3.09%
MRKMerck & Co. Inc.+4.20%+3.93%
UNHUnitedHealth Group Incorporated Common Stock (DE)+10.08%+1.22%
TMOThermo Fisher Scientific Inc.+7.84%+1.12%
AMGNAmgen Inc.+18.69%+3.71%
GILDGilead Sciences Inc.+20.55%+4.19%